FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897519081> ?p ?o ?g. }

• W2897519081 abstract "The standard statistical model used in the primary efficacy analysis for phase III Alzheimer's disease (AD) trials is the mixed effects model for repeated measures (MMRM)1. The MMRM is a large parametric model without any assumption on the underling longitudinal trajectory and is well accepted by regulatory agencies. The primary efficacy analysis, however, hinges only on the baseline and end-of-study assessments and other intermediate assessments provide little information on the test of efficacy hypothesis, leading to inefficient use of study data and lower power. We developed a novel proportional MMRM (PMMRM) which assumes the efficacy effect from the active treatment is proportional to the change in the placebo group at each post-baseline visit. We simulate clinical trials with different sample sizes and durations, and allow extended follow-up for early enrollees while awaiting the late ones to complete the study. Individual data are simulated from MMRM or proportional MMRM based on multivariate normal distribution. We then compared the power and type I error between MMRM and PMMRM models. Type I error for PMMRM is well controlled, but is above the nominal 5% for MMRM. Compared with MMRM, the PMMRM leads to large increase in power (Figure 1), and utilizes data from extended follow-up for early enrollees. More simulation will be done to evaluate the power increase for different type of covariance structures. Power (Type I error) comparison. No dropout is simulated. When the last enrollee completes the 4-year trial, we assume 50% complete extended follow-up (EF) assessment at year 5, then 25% at year 6. The baseline mean is 1, and the change from baseline for placebo is 0.2, 0.6, 0.9,1.1 during the 4 years, and 1.3, 1.3 for the 2-year EF. Within-subject error variance 0.5. Both models include random intercept and its variance is 0.5. The use of PMMRM can largely reduce the sample size for AD trials. The PMMRM enables all study assessments to contribute to the test of null hypothesis and can offers flexibility by allowing a consistent proportion or multiple proportions (e.g. easily take into account of practice effect by using a different proportion for the 1st visit post baseline). The PMMRM can be implemented using standard SAS software, thus has great potential to serve as an alternative primary analysis model to the MMRM." @default.
• W2897519081 created "2018-10-26" @default.
• W2897519081 creator A5021959578 @default.
• W2897519081 creator A5022462599 @default.
• W2897519081 creator A5035514608 @default.
• W2897519081 creator A5038805449 @default.
• W2897519081 creator A5049785357 @default.
• W2897519081 creator A5062159344 @default.
• W2897519081 creator A5068373508 @default.
• W2897519081 creator A5073392602 @default.
• W2897519081 date "2018-07-01" @default.
• W2897519081 modified "2023-10-16" @default.
• W2897519081 title "P2‐076: A NOVEL ALTERNATIVE MODEL TO MMRM AS THE PRIMARY MODEL FOR SPORADIC AD CLINICAL TRIALS: THE PROPORTIONAL MMRM" @default.
• W2897519081 doi "https://doi.org/10.1016/j.jalz.2018.06.761" @default.
• W2897519081 hasPublicationYear "2018" @default.
• W2897519081 type Work @default.
• W2897519081 sameAs 2897519081 @default.
• W2897519081 citedByCount "0" @default.
• W2897519081 crossrefType "journal-article" @default.
• W2897519081 hasAuthorship W2897519081A5021959578 @default.
• W2897519081 hasAuthorship W2897519081A5022462599 @default.
• W2897519081 hasAuthorship W2897519081A5035514608 @default.
• W2897519081 hasAuthorship W2897519081A5038805449 @default.
• W2897519081 hasAuthorship W2897519081A5049785357 @default.
• W2897519081 hasAuthorship W2897519081A5062159344 @default.
• W2897519081 hasAuthorship W2897519081A5068373508 @default.
• W2897519081 hasAuthorship W2897519081A5073392602 @default.
• W2897519081 hasConcept C102959455 @default.
• W2897519081 hasConcept C105795698 @default.
• W2897519081 hasConcept C117251300 @default.
• W2897519081 hasConcept C119340705 @default.
• W2897519081 hasConcept C149782125 @default.
• W2897519081 hasConcept C178650346 @default.
• W2897519081 hasConcept C33923547 @default.
• W2897519081 hasConcept C40696583 @default.
• W2897519081 hasConcept C96608239 @default.
• W2897519081 hasConcept C99476002 @default.
• W2897519081 hasConceptScore W2897519081C102959455 @default.
• W2897519081 hasConceptScore W2897519081C105795698 @default.
• W2897519081 hasConceptScore W2897519081C117251300 @default.
• W2897519081 hasConceptScore W2897519081C119340705 @default.
• W2897519081 hasConceptScore W2897519081C149782125 @default.
• W2897519081 hasConceptScore W2897519081C178650346 @default.
• W2897519081 hasConceptScore W2897519081C33923547 @default.
• W2897519081 hasConceptScore W2897519081C40696583 @default.
• W2897519081 hasConceptScore W2897519081C96608239 @default.
• W2897519081 hasConceptScore W2897519081C99476002 @default.
• W2897519081 hasIssue "7S_Part_12" @default.
• W2897519081 hasLocation W28975190811 @default.
• W2897519081 hasOpenAccess W2897519081 @default.
• W2897519081 hasPrimaryLocation W28975190811 @default.
• W2897519081 hasRelatedWork W157636944 @default.
• W2897519081 hasRelatedWork W2018627549 @default.
• W2897519081 hasRelatedWork W2020480331 @default.
• W2897519081 hasRelatedWork W2053970827 @default.
• W2897519081 hasRelatedWork W2058836072 @default.
• W2897519081 hasRelatedWork W2149823923 @default.
• W2897519081 hasRelatedWork W4233860837 @default.
• W2897519081 hasRelatedWork W4298209841 @default.
• W2897519081 hasRelatedWork W4317557429 @default.
• W2897519081 hasRelatedWork W4382404049 @default.
• W2897519081 hasVolume "14" @default.
• W2897519081 isParatext "false" @default.
• W2897519081 isRetracted "false" @default.
• W2897519081 magId "2897519081" @default.
• W2897519081 workType "article" @default.